The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | New EHA guidelines for patient-reported outcome assessment in MPNs
Esther Oliva, MD, London North West University Healthcare NHS Trust, London, UK, discusses the new European Hematology Association (EHA) Guidelines for patient-reported outcome (PRO) assessment in myeloproliferative neoplasm (MPN) clinical trials, highlighting the importance of capturing the patient’s experience of living with the disease, beyond objective markers. Dr Oliva explains that the guidelines provide practical international recommendations for the use of patient-reported outcome measures in trials, emphasizing the need for a tailored approach to selecting measures, standardized administration, and transparent reporting. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
